Jagsonpal Pharmaceuticals Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/jnf7sdzqht8kgtx0ujhkurjz.pdf

Key Takeaways


Core Business Recovery

Gupta: "We actually do not go for large opportunities. We believe being a meaningful player in sub-INR100 crores molecule or sub-INR100 crores opportunity is a far more manageable, profitable and sustainable area of opportunity."

Yash Pharma Acquisition & Therapy Expansion


Margin Trajectory & Operating Leverage

Gupta: "We are confident of 22% plus for sure. Difficult to predict the last number in the sense, in terms of where we will end up. But we are fairly confident on improving our H1 margins in the current year for sure and delivering a 100 bps to 150 bps, if not more, margin expansion year on year over the next three years."

Field Force Productivity & Growth Mechanics

Gupta: "What we really own or what is our strength is presence of medical rep in doctor's chamber, given that he has been visiting doctors for over 40 years... it's really our ownership of the doctor's chamber that we are good at."

Capital Allocation & Inorganic Strategy

Gupta: "This is a difficult one because acquisitions are 60% strategy and 40% opportunity."

Guidance & Commitments

CommitmentSpecificsTimeline
Organic revenue growth12% to 14% annually, built on 3–5% each from volume, price, and new productsMedium term
FY25 operating margin22%+ (pre-ESOP), upgraded from 20%+FY25
Annual margin expansion100–150 bps (if not more) YoYNext 3–4 years
Long-term EBITDA marginCloser to 30%Within 3 years
Sales per MRReach ₹4.5 lakhs from current ~₹2.8 lakhsNext 3 years
New product cadence2–3 new launches per division per year, across all four therapies with slight gynae biasOngoing
Full-year organic growthHigher than 14% (weak H2 FY24 base provides tailwind)FY25

Key Metrics

MetricQ2 FY25
Revenue₹74.7 cr, +29.2% YoY
Revenue (H1 FY25)₹136.1 cr, +15.3% YoY
Operating EBITDA (pre-ESOP)₹18.4 cr, +46.6% YoY
Operating margin (pre-ESOP)24.6%, expanded 290 bps YoY
Net profit₹11.4 cr, +53% YoY
Net profit margin15.3%
Net profit (H1 FY25)₹16.8 cr, +12% YoY; includes ₹3.3 cr exceptional acquisition cost in Q1
Cash balance₹93.4 cr as of 30 Sep, up ₹15.8 cr
Organic revenue growth (core business, ex-Yash Pharma)5% YoY
Yash Pharma division revenue contribution~₹14 cr out of ₹74.7 cr
Gross margin~65%
Field force size900+ MRs
Field force productivity₹2.8 lakhs per MR per month
MR attrition rate20%+, close to 30% in H2 last year
EBITDA margin guidance (FY25)22%+
Organic revenue growth guidance (medium term)12% to 14%